{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:12:06Z","timestamp":1779923526042,"version":"3.53.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Reducing the treatment duration for chronic hepatitis C could be an important tool in the effort to reach the elimination goals set by the World Health Organization. The current challenge is to predict the target group who will achieve sustained virological response at week 12 (SVR12) with shorter treatment duration. The aim of this exploratory study was to characterize immune subsets with focus on inhibitory receptors in patients who experienced SVR12 or virological relapse following four weeks treatment with glecaprevir\/pibrentasvir with or without ribavirin. A total of 32 patients were included in this study of whom 21 achieved SVR12 and 11 had virological relapse. All available samples at baseline (n = 31) and end of treatment (EOT) (n = 30) were processed for flow cytometric analysis in order to measure the expression of PD-1, 2B4, BY55, CTLA-4, TIM-3 and LAG-3 on 12 distinct T cell subsets. At baseline, patients with SVR12 (n=21) had numerically lower frequencies of inhibitory receptors for 83% (60\/72) of the investigated T-cell subtypes. The most significant difference observed between the two groups was a lower frequency of stem cell-like memory T-cells CD4<jats:sup>+<\/jats:sup>PD1<jats:sup>+<\/jats:sup> in the SVR group (p = 0.007). Furthermore, we observed a significant positive correlation between baseline viral load and the expression of PD-1 on the total CD8<jats:sup>+<\/jats:sup> T-cells and effector memory T-cells CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> for patients with virological relapse. This study suggests a measurable immunologic phenotype at baseline of patients achieving SVR12 after short treatment compared to patients with virological relapse.<\/jats:p>","DOI":"10.3389\/fcimb.2022.885824","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T04:45:43Z","timestamp":1656305143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C"],"prefix":"10.3389","volume":"12","author":[{"given":"Lone Wulff","family":"Madsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer Brehm","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"\u00d8vrehus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorthe Marie Sj\u00f8dahl","family":"Bryde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Kinggaard","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Thue","family":"Lillevang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/hep.29921","article-title":"Baseline Intrahepatic and Peripheral Innate Immunity are Associated With Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy","volume":"68","author":"Alao","year":"2018","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors During Chronic Viral Infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.4254\/wjh.v7.i12.1617","article-title":"Predictive Factors Associated With Hepatitis C Antiviral Therapy Response","volume":"7","author":"Cavalcante","year":"2015","journal-title":"World J. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","article-title":"Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1","volume":"131","author":"Conjeevaram","year":"2006","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.12688\/wellcomeopenres.16594.2","article-title":"Strategic Treatment Optimization for HCV (STOPHCV1): A Randomised Controlled Trial of Ultrashort Duration Therapy for Chronic Hepatitis C","volume":"6","author":"Cooke","year":"2021","journal-title":"Wellcome Open Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 Expression on HIV-Specific T Cells is Associated With T-Cell Exhaustion and Disease Progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063818","article-title":"A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Chronic Hepatitis C Virus Infection","volume":"8","author":"Gardiner","year":"2013","journal-title":"PLoS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.4049\/jimmunol.180.6.3637","article-title":"Cutting Edge: Programmed Death-1 Expression is Increased on Immunocytes in Chronic Hepatitis C Virus and Predicts Failure of Response to Antiviral Therapy: Race-Dependent Differences","volume":"180","author":"Golden-Mason","year":"2008","journal-title":"J. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nrgastro.2012.101","article-title":"Genetics of IL28B and HCV\u2013response to Infection and Treatment","volume":"9","author":"Hayes","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.jhep.2014.06.035","article-title":"Innate and Adaptive Immune Responses in HCV Infections","volume":"61","author":"Heim","year":"2014","journal-title":"J. Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.12688\/wellcomeopenres.15411.1","article-title":"Treatment Optimisation for Hepatitis C in the Era of Combination Direct-Acting Antiviral Therapy: A Systematic Review and Meta-Analysis","volume":"4","author":"Jones","year":"2019","journal-title":"Wellcome Open Res."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00487","article-title":"The Role of PD-1 in Acute and Chronic Infection","volume":"11","author":"Jubel","year":"2020","journal-title":"Front. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.3390\/ijms21165644","article-title":"Adaptive Immune Response Against Hepatitis C Virus","volume":"21","author":"Kemming","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/jvh.13652","article-title":"Soluble Inflammatory Mediators Identify HCV Patients Who may be Cured With Four Weeks of Antiviral Treatment","volume":"29","author":"Khera","year":"2022","journal-title":"J. Viral Hepat."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042094","article-title":"Ribavirin Exerts Differential Effects on Functions of Cd4+ Th1, Th2, and Regulatory T Cell Clones in Hepatitis C","volume":"7","author":"Langhans","year":"2012","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/hep.28877","article-title":"Short-Duration Treatment With Elbasvir\/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/liv.13932","article-title":"Clinical Significance of Detectable and Quantifiable HCV RNA at the End of Treatment With Ledipasvir\/Sofosbuvir in GT1 Patients","volume":"38","author":"Maasoumy","year":"2018","journal-title":"Liver Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1111\/liv.14991","article-title":"Inferior Cure Rate in Pilot Study of 4-Week Glecaprevir\/Pibrentasvir Treatment With or Without Ribavirin of Chronic Hepatitis C","volume":"41","author":"Madsen","year":"2021","journal-title":"Liver Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The Who's Who of T-Cell Differentiation: Human Memory T-Cell Subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV-Specific CD8+ T Cell Function by Interferon-Free Therapy","volume":"61","author":"Martin","year":"2014","journal-title":"J. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1172\/jci75938","article-title":"Endogenous Intrahepatic IFNs and Association With IFN-Free HCV Treatment Outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1053\/j.gastro.2008.02.033","article-title":"Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade is Defined by PD-1 Expression and Compartmentalization","volume":"134","author":"Nakamoto","year":"2008","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/hepr.13186","article-title":"Restoration of Natural Killer Cell Activity by Interferon-Free Direct-Acting Antiviral Combination Therapy in Chronic Hepatitis C Patients","volume":"48","author":"Nakamura","year":"2018","journal-title":"Hepatol. Res."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab118","article-title":"Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8(+) T-Cell Function","volume":"8","author":"Orr","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"16060","DOI":"10.1038\/s41598-020-73137-6","article-title":"Decrease of T-Cells Exhaustion Markers Programmed Cell Death-1 and T-Cell Immunoglobulin and Mucin Domain-Containing Protein 3 and Plasma IL-10 Levels After Successful Treatment of Chronic Hepatitis C","volume":"10","author":"Osuch","year":"2020","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/mra.00755-21","article-title":"Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype From a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment","volume":"10","author":"Pedersen","year":"2021","journal-title":"Microbiol. Resour. Announc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.gastro.2018.08.061","article-title":"Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection","volume":"156","author":"Rehermann","year":"2019","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01470","article-title":"Peripheral PD-1(+) T Cells Co-Expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection","volume":"10","author":"Romani","year":"2019","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1084\/jem.20100388","article-title":"Broadly Directed Virus-Specific CD4+ T Cell Responses are Primed During Acute Hepatitis C Infection, But Rapidly Disappear From Human Blood With Viral Persistence","volume":"209","author":"Schulze Zur Wiesch","year":"2012","journal-title":"J. Exp. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function","volume":"149","author":"Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422x-7-310","article-title":"PD-1 Expression on Peripheral CD8+ TEM\/TEMRA Subsets Closely Correlated With HCV Viral Load in Chronic Hepatitis C Patients","volume":"7","author":"Shen","year":"2010","journal-title":"Virol. J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/s0168-8278(99)80093-2","article-title":"Ribavirin Polarizes Human T Cell Responses Towards a Type 1 Cytokine Profile","volume":"30","author":"Tam","year":"1999","journal-title":"J. Hepatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"8050","DOI":"10.3748\/wjg.v22.i35.8050","article-title":"Second-Generation Direct-Acting-Antiviral Hepatitis C Virus Treatment: Efficacy, Safety, and Predictors of SVR12","volume":"22","author":"Werner","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15050","article-title":"TCF1(+) Hepatitis C Virus-Specific CD8(+) T Cells are Maintained After Cessation of Chronic Antigen Stimulation","volume":"8","author":"Wieland","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.885824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T04:45:47Z","timestamp":1656305147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.885824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":34,"alternative-id":["10.3389\/fcimb.2022.885824"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.885824","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"article-number":"885824"}}